123 related articles for article (PubMed ID: 35512109)
1. Now or later: Health impacts of delaying single-dose HPV vaccine implementation in a high-burden setting.
Burger EA; Laprise JF; Sy S; Regan MC; Prem K; Jit M; Brisson M; Kim JJ
Int J Cancer; 2022 Nov; 151(10):1804-1809. PubMed ID: 35512109
[TBL] [Abstract][Full Text] [Related]
2. Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country.
Burger EA; Campos NG; Sy S; Regan C; Kim JJ
Vaccine; 2018 Aug; 36(32 Pt A):4823-4829. PubMed ID: 29807710
[TBL] [Abstract][Full Text] [Related]
3. Model-estimated effectiveness of single dose 9-valent HPV vaccination for HIV-positive and HIV-negative females in South Africa.
Tan N; Sharma M; Winer R; Galloway D; Rees H; Barnabas RV
Vaccine; 2018 Aug; 36(32 Pt A):4830-4836. PubMed ID: 29891348
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras.
Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB
Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157
[TBL] [Abstract][Full Text] [Related]
5. Single-dose HPV vaccination efficacy among adolescent girls and young women in Kenya (the KEN SHE Study): study protocol for a randomized controlled trial.
Barnabas RV; Brown ER; Onono M; Bukusi EA; Njoroge B; Winer RL; Donnell D; Galloway D; Cherne S; Heller K; Leingang H; Morrison S; Rechkina E; McClelland RS; Baeten JM; Celum C; Mugo N;
Trials; 2021 Sep; 22(1):661. PubMed ID: 34579786
[TBL] [Abstract][Full Text] [Related]
6. Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in Switzerland.
Kind AB; Pavelyev A; Kothari S; El Mouaddin N; Schmidt A; Morais E; Guggisberg P; Lienert F
BMC Public Health; 2020 May; 20(1):671. PubMed ID: 32398057
[TBL] [Abstract][Full Text] [Related]
7. Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis.
Drolet M; Laprise JF; Martin D; Jit M; Bénard É; Gingras G; Boily MC; Alary M; Baussano I; Hutubessy R; Brisson M
Lancet Infect Dis; 2021 Nov; 21(11):1598-1610. PubMed ID: 34245682
[TBL] [Abstract][Full Text] [Related]
8. The Clinical and Economic Impact of a Nonavalent Versus Bivalent Human Papillomavirus National Vaccination Program in Taiwan.
Chou HH; Chang SC; Sukarom I; Saxena K; Pavelyev A; Wu YH; Chang CJ
Value Health Reg Issues; 2022 Nov; 32():79-87. PubMed ID: 36116338
[TBL] [Abstract][Full Text] [Related]
9. Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries.
Brisson M; Kim JJ; Canfell K; Drolet M; Gingras G; Burger EA; Martin D; Simms KT; Bénard É; Boily MC; Sy S; Regan C; Keane A; Caruana M; Nguyen DTN; Smith MA; Laprise JF; Jit M; Alary M; Bray F; Fidarova E; Elsheikh F; Bloem PJN; Broutet N; Hutubessy R
Lancet; 2020 Feb; 395(10224):575-590. PubMed ID: 32007141
[TBL] [Abstract][Full Text] [Related]
10. Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence.
Bogaards JA; Coupé VM; Xiridou M; Meijer CJ; Wallinga J; Berkhof J
Epidemiology; 2011 Jul; 22(4):505-15. PubMed ID: 21540743
[TBL] [Abstract][Full Text] [Related]
11. Burden of disease associated with cervical cancer in malaysia and potential costs and consequences of HPV vaccination.
Aljunid S; Zafar A; Saperi S; Amrizal M
Asian Pac J Cancer Prev; 2010; 11(6):1551-9. PubMed ID: 21338196
[TBL] [Abstract][Full Text] [Related]
12. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
Gomez JA; Lepetic A; Demarteau N
BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study.
Jit M; Brisson M; Portnoy A; Hutubessy R
Lancet Glob Health; 2014 Jul; 2(7):e406-14. PubMed ID: 25103394
[TBL] [Abstract][Full Text] [Related]
14. Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths.
Van Kriekinge G; Castellsagué X; Cibula D; Demarteau N
Vaccine; 2014 Feb; 32(6):733-9. PubMed ID: 24291200
[TBL] [Abstract][Full Text] [Related]
15. Estimating the impact of human papillomavirus (HPV) vaccination on HPV prevalence and cervical cancer incidence in Mali.
Tracy L; Gaff HD; Burgess C; Sow S; Gravitt PE; Tracy JK
Clin Infect Dis; 2011 Mar; 52(5):641-5. PubMed ID: 21252142
[TBL] [Abstract][Full Text] [Related]
16. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).
Kim JJ; Sharma M; O'Shea M; Sweet S; Diaz M; Sancho-Garnier H; Seoud M
Vaccine; 2013 Dec; 31 Suppl 6():G65-77. PubMed ID: 24331822
[TBL] [Abstract][Full Text] [Related]
17. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
18. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
Patel C; Brotherton JM; Pillsbury A; Jayasinghe S; Donovan B; Macartney K; Marshall H
Euro Surveill; 2018 Oct; 23(41):. PubMed ID: 30326995
[TBL] [Abstract][Full Text] [Related]
19. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
[TBL] [Abstract][Full Text] [Related]
20. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine.
Goldie SJ; Kohli M; Grima D; Weinstein MC; Wright TC; Bosch FX; Franco E
J Natl Cancer Inst; 2004 Apr; 96(8):604-15. PubMed ID: 15100338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
